Not a good buy right now: price (4.31) is below the key pivot (4.538) and showing near-term weakness (pre-market -3.22%), which is not ideal for an impatient entry.
Upside exists longer-term (single analyst Buy with $8 target; payer coverage expansion), but today’s technical/setup does not provide a strong immediate-risk entry.
Best stance now is Hold (or wait for an intraday reclaim of ~4.54+ / confirmation bounce off ~4.21 support before treating as a buy).
Technical Analysis
Trend/price context: Current price 4.31 is below Pivot 4.538, suggesting a slightly bearish/defensive near-term posture.
Momentum: MACD histogram -0.107 (below zero) but negatively contracting → downside momentum is easing, yet still not bullish.
RSI(6) 44.59 (neutral) → no oversold bounce signal.
Moving averages: Converging MAs → consolidation/indecision rather than a confirmed uptrend.
Levels: Support S1 4.208 then S2 4.004; Resistance R1 4.869 then R2 5.073.
Pattern-based projection (similar candlesticks): suggests modest upside odds (1D ~+1.05%, 1W ~+5.48%, 1M ~+13.86%), but this is not corroborated by strong momentum indicators today.
on expanded national payer coverage; cites ~45M additional lives and ~100M total covered lives, potentially unlocking pediatric opportunity.
Neutral/Negative Catalysts
Near-term tape weakness: pre-market -3.22% while broader market is risk-off (S&P 500 -1.06%).
Technicals not confirming a buy: price below pivot, MACD still negative, and no proprietary buy signals today.
Profitability still negative: net income remains a loss (2025/Q3 net income -2.32M) and EPS declined YoY.
No near-term news flow in the past week to act as an immediate catalyst.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 811,414 (+21.72% YoY) → solid top-line growth off a small base.
Net income: -2,321,503 (improved +28.97% YoY) → losses narrowing but still meaningfully negative.
EPS: -0.24 (down -4.00% YoY) → per-share profitability did not improve.
Gross margin: 83.3% (down -2.50% YoY) → still very high, but slight compression.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Rating/target trend: Craig-Hallum maintained a Buy and raised the price target to $8 from $7 (2025-12-22).
Wall Street pro view (pros): payer coverage expansion materially increases addressable covered lives and could accelerate adoption/revenue.
Wall Street con view (cons): execution and scaling risk implied by continued losses/EPS pressure; current chart lacks a clear bullish trigger.
Influential/politician activity: No recent congress trading data available (last 90 days); no politician transactions provided.
Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.350
Low
8
Averages
8
High
8
Current: 4.350
Low
8
Averages
8
High
8
Craig-Hallum
Buy
maintain
$7 -> $8
AI Analysis
2025-12-22
Reason
Craig-Hallum
Price Target
$7 -> $8
AI Analysis
2025-12-22
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Neuraxis to $8 from $7 and keeps a Buy rating on the shares after the company announced that they have been included in coverage from a large, national payer. This coverage expansion adds approximately 45M lives, bringing total national coverage for IBStim to nearly 100M. The Anthem win adds coverage for as much as 20% of NeurAxis's pediatric opportunity, and the firm believes it really unlocks the opportunity itself.
Craig-Hallum
Chase Knickerbocker
Buy
initiated
$7
2025-06-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$7
2025-06-17
initiated
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRXS
